{"nctId":"NCT01091662","briefTitle":"Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic","startDateStruct":{"date":"2010-06"},"conditions":["Epilepsy"],"count":172,"armGroups":[{"label":"eslicarbazepine acetate 1600 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Eslicarbazepine acetate 1600 mg"]},{"label":"eslicarbazepine acetate 1200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Eslicarbazepine acetate 1200 mg"]}],"interventions":[{"name":"Eslicarbazepine acetate 1600 mg","otherNames":[]},{"name":"Eslicarbazepine acetate 1200 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of partial epilepsy as defined in the Classification of Seizures of the International League Against Epilepsy (ILAE) (simple partial seizures with observable motor component, or complex, with or without secondary generalization)\n\n  * Medical history of seizures;\n  * Absence of confounding factors (pseudoseizures, syncope);\n  * Documented EEG recording (done within 5 years prior to screening) consistent with focal onset epilepsy\n* Documented CT or MRI scan conducted within 10 years prior to screening, showing the absence of a structural abnormality (eg, tumor or malformation)\n* ≥ 4 partial onset seizures during the 8 weeks prior screening with no 28-day seizure free period\n* Stable treatment with 1-2 AEDs during the last 4 weeks prior to screening\n* Subjects must have the ability to comprehend the informed consent form and be willing to provide informed consent. For subjects who are unable to comprehend the written consent, a witness/caregiver who is able to describe and provide an understanding of the informed consent to the subject must sign the consent form on behalf of the subject.\n* Subjects must give written informed consent prior to participation in the study. For subjects \\<18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. Subjects of Asian ancestry are required to give written informed consent for genotyping. All subjects must sign a HIPAA Form. All females of child bearing potential must also sign the \"Women of Childbearing Potential\" Addendum.\n* A female subject is eligible to enter and participate in the study if she is of:\n\n  * Non-childbearing potential (ie, physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal);\n  * Child-bearing potential (all females ≤65 years of age), has a negative pregnancy test at screening and agrees to satisfy contraception requirements\n\nExclusion Criteria:\n\n* Subjects with only simple partial seizures without a motor component\n* Presence of generalized seizure syndromes (eg, juvenile myoclonic epilepsy or Lennox-Gastaut syndrome)\n* History of pseudo-seizures\n* Current seizures related to an acute medical illness\n* Seizures secondary to metabolic, toxic or infectious disorder or drug abuse\n* Status epilepticus within 2 years prior to screening\n* Seizures only occurring in a cluster pattern\n* Subjects taking 2 of the following sodium channel blocking AEDs: phenytoin, carbamazepine, oxcarbazepine, or lamotrigine\n* Subjects taking 2 AEDs with both being in the upper dose range (defined as approximately two-thirds of the defined daily dose)\n* Subjects taking more than 2 AEDs\n* Subjects with progressive structural central nervous system lesion or progressive encephalopathy\n* Psychiatric exclusion criteria\n* Medical exclusion criteria: known renal insufficiency (estimated creatinine clearance \\[CrCL\\]) \\<60 mL/min based on serum creatinine using the Cockcroft-Gault formula\n* Clinical and laboratory exclusion criteria: Subjects of Asian ancestry who tests positive for the presence of the HLA-B\\*1502 allele\n* Subjects who have been on benzodiazepines, phenobarbital, or primidone on a regular basis within 3 months prior to screening\n* Subjects taking antipsychotics, tricyclic antidepressants, anxiolytics, sedative hypnotics including non-benzodiazepines, central opioid agonists/antagonists, monoamine oxidase inhibitors (MAOIs) within at least 5 half lives (or for at least 2 weeks whichever is longer) prior to randomization\n* Subjects presently on felbamate or vigabatrin","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method","description":"Cumulative exit rate was defined as the proportion of subjects meeting at least one of the following five exit criteria over a 16-week study period (from start of AED taper/con. period (Wk 3) to end of double blind monotherapy period (Wk 18)).1.One episode of status epilepticus.2.One secondary gen. partial seizure (in subjects who did not have gen.seizures during 6 mo. prior to screening).3.A two fold increase in any consecutive 28 day seizure rate compared to the highest consecutive 28 day seizure rate during the 8 week baseline period. 4.A two fold increase in any consecutive 2 day seizure rate compared to the highest consecutive 2 day seizure rate during the 8 week baseline period. If the highest number of seizures in any consecutive 2 day period during the 8 week baseline was 1 then 3 seizures in a consecutive 2 day period was required to exit.\n\n5.Worsening of seizures or increase in seizure frequency considered serious or requiring intervention as judged by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.156","spread":null},{"groupId":"OG001","value":"0.128","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Subjects That Are Seizure-free During the 10-week Double-blind Monotherapy Treatment Period.","description":"Seizure-free subjects during the monotherapy period were determined as subjects who had seizure assessments during the monotherapy period, and did not have any seizures in the 10 weeks between Visits 6 and 9 (Weeks 9 through 18). Subjects who discontinued during this period were considered not seizure-free even if they were seizure-free at the time of discontinuation, i.e., to be considered seizure-free, subjects must complete the 10-week period without any seizures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Seizure-free During the Last 4 Weeks on Eslicarbazepine Acetate Monotherapy.","description":"Percentage of participants that were Seizure-free during the last four weeks of monotherapy were determined as subjects who had seizure assessments during the 4 weeks between Visits 8 and 9 (Weeks 15 through 18), and did not have any seizures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Completion Rate (% of Subjects Completing the 18 Weeks of Double-blind Treatment).","description":"Subjects completing the study were determined as subjects who completed the 18 weeks of double-blind treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Completion Rate During the 10 Weeks of Monotherapy (% of Subjects Entering the Monotherapy Period Who Complete).","description":"Monotherapy completion rate was defined as the proportion (%) of subjects entering the monotherapy period who completed the 10 weeks of monotherapy treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time on Eslicarbazepine Acetate Monotherapy.","description":"The start of the monotherapy period was defined as the date of termination of all other AEDs while taking study monotherapy medication. Time on monotherapy was defined from the start of monotherapy period to the last dose of monotherapy treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Seizure Frequency From Baseline.","description":"The relative (%) change in standardized seizure frequency was evaluated for four periods: titration (Weeks 1 to 2), AED taper/conversion (Weeks 3 to 8), monotherapy (Weeks 9 to 18), and double-blind (Weeks 1 to 18).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.1","spread":null},{"groupId":"OG001","value":"-47.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.3","spread":null},{"groupId":"OG001","value":"-35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.4","spread":null},{"groupId":"OG001","value":"-42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.7","spread":null},{"groupId":"OG001","value":"-52.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate (Proportion [%] of Subjects With a ≥50% Reduction of Seizure Frequency From Baseline).","description":"Responder rate was defined as the proportion (%) of subjects with a ≥ 50% reduction of seizure frequency from baseline. This analysis was done for the titration (Weeks 1 to 2), AED taper/conversion (Weeks 3 to 8), monotherapy (Weeks 9 to 18), and double-blind (Weeks 1 to 18) periods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null},{"groupId":"OG001","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"37.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"46.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Subjects Reaching Each Exit Criteria","description":"The proportion (%) of subjects reaching each of the 5 exit criteria-1.One episode of status epilepticus.2.One secondary gen. partial seizure (in subjects who did not have gen.seizures during 6 mo. prior to screening).3.A two fold increase in any consecutive 28 day seizure rate compared to the highest consecutive 28 day seizure rate during the 8 week baseline period. 4.A two fold increase in any consecutive 2 day seizure rate compared to the highest consecutive 2 day seizure rate during the 8 week baseline period. If the highest number of seizures in any consecutive 2 day period during the 8 week baseline was 1 then 3 seizures in a consecutive 2 day period was required to exit.\n\n5.Worsening of seizures or increase in seizure frequency considered serious or requiring intervention as judged by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Total Score From Baseline in 31-Item Quality of Life in Epilepsy (QOLIE-31).","description":"The QOLIE-31 overall score was obtained by using a weighted average of multi-item scale scores. The recorded responses were converted to 0-100 point scales. The mean of the individual item scores in each subgroup were calculated, with higher converted scores reflecting better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"12.03"},{"groupId":"OG001","value":"5.8","spread":"11.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"11.48"},{"groupId":"OG001","value":"4.7","spread":"13.70"}]}]}]},{"type":"SECONDARY","title":"Change in Total Score in Montgomery-Asberg Depression Rating Scale (MADRS),From Baseline .","description":"The total score of MADRS is defined as the sum of all individual item scores. From 0-60, high score indicates more severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"3.69"},{"groupId":"OG001","value":"-1.8","spread":"4.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"6.47"},{"groupId":"OG001","value":"-1.6","spread":"4.54"}]}]}]},{"type":"SECONDARY","title":"Change in Total Score of MADRS From Baseline in Those Subjects With a MADRS Score of ≥14 at Randomization.","description":"The total score of MADRS is defined as the sum of all individual item scores. From 0-60, higher score indicates more severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"4.30"},{"groupId":"OG001","value":"-6.6","spread":"4.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"6.72"},{"groupId":"OG001","value":"-4.1","spread":"7.58"}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Subjects With Increase of Body Weight >= 7% From Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Subjects With Normal Baseline Sodium Reaching Blood Sodium ≤135 mmol/L, ≤130 mmol/L, and ≤125 mmol/L.","description":"Proportion (%) of Subjects With Normal Baseline Sodium Reaching Blood Sodium ≤135 mmol/L, ≤130 mmol/L, and ≤125 mmol/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"20.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Events in Each Classification of the Columbia Suicide Severity Rating Scale (C SSRS).","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Standardized Seizure Frequency (SSF) by Period","description":"Seizure frequency was evaluated by using a standardized frequency per 4 weeks (28 days). It was evaluated for five periods: baseline (Weeks -8 to -1), titration (Weeks 1 to 2), AED taper/conversion (Weeks 3 to 8), monotherapy (Weeks 9 to 18), and double-blind (Weeks 1 to 18).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"7.75"},{"groupId":"OG001","value":"5.2","spread":"5.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"5.89"},{"groupId":"OG001","value":"8.7","spread":"7.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"6.16"},{"groupId":"OG001","value":"6.4","spread":"8.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"9.68"},{"groupId":"OG001","value":"5.1","spread":"5.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"6.10"},{"groupId":"OG001","value":"5.0","spread":"5.62"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":["Headache","Dizziness","Nausea","Nasopharyngitis","Solmnolence"]}}}